Among them, CXCR2 was drastically upregulated in the IBD and adenoma stage, which is corroborated by the general upregulation of its ligands, CXCL1-3 and CXCL5-8 (Figure 1). This evidence concerns the gene CXCL13 and inflammatory bowel disease.